A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01675232|
Recruitment Status : Completed
First Posted : August 29, 2012
Last Update Posted : July 29, 2014
|Condition or disease||Intervention/treatment||Phase|
|Atopic Dermatitis||Other: Soak and smear Other: Dry Smear||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Investigator-Blinded Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Active Comparator: Soak and smear
Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
Other: Soak and smear
Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
Active Comparator: Dry smear
Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
Other: Dry Smear
Corticosteroid ointment applied to dry skin twice a day.
- Efficacy of corticosteroid application regimen as assessed by the Eczema Area and Severity Index (EASI) [ Time Frame: 2 weeks ]
- Effect of corticosteroid ointment application regimens on serum cortisol [ Time Frame: 2 weeks after application of topical corticosteroids ]
- Frequency of atopic dermatitis flares in the 3 months following the two-week treatment regimen [ Time Frame: 3 months ]
- Adverse effects associated with each corticosteroid application regimen [ Time Frame: 3 months ]Characterize and quantify adverse effects associated with each corticosteroid application regimen.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01675232
|United States, Connecticut|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Richard J Antaya, MD||Yale University|